Celldrive 3D receives 325,000 euros from the Neotec 2023 program, granted by the CDTI, to accelerate its project to develop translational bioinks for 3D bioprinting
Celldrive 3D has been awarded a grant of 325,000 euros granted within the Neotec program granted by the CDTI, a body under the Ministry of Science and Innovation os Spain, with a project aimed at developing translational bioinks for 3D bioprinting, with which it has managed to be within of the 10 best valued projects
Celldrive 3D has been awarded a grant of 325,000 euros granted within the Neotec program granted by the CDTI, a body under the Ministry of Science and Innovation os Spain, with a project aimed at developing translational bioinks for 3D bioprinting, with which it has managed to be within of the 10 best valued projects.
CellDrive 3D is a technology-based company promoted by the University of Valladolid (Spain) and by the venture capital fund BeAble INNVIERTE KETs FUND. The company was created in 2020 with the aim of developing and commercializing its technological platform for the development of advanced bioinks to be applied in the field of tissue engineering and regenerative medicine.
This funding will be invested in the development of advanced bioinks to be applied in the field of tissue engineering and regenerative medicine, which will favor the translation of bioprinted tissues to the clinic.
Celldrive 3D offers a modular technology to develop translational bioinks for 3D bioprinting, the only synthetic bioinks capable of promoting cell adhesion and proliferation while remaining stable after printing without the use of crosslinkers or photoinitiators. Its technology gives the material the required properties of an advanced bioink for use in 3D bioprinting.
Celldrive 3D bio-ink, fully reproducible and sterile, is R&D market-ready and is patented in the main geographic areas for the target market: Europe, China, Japan and USA. The bioink is inspired by the sequence of human elastin, a key extracellular matrix protein that provides resilience and elasticity to many mammalian tissues while exhibiting excellent biocompatibility. In addition, its composition is free of animal products and is based on an amino acid structure that reduces the risk of an immune response. Celldrive 3D's bioink is compatible with most printing technologies on the market and its modular technology offers the possibility to adapt the physical properties to future versions of bioprinters.
The bioink can be used with different types of cells in single culture and even in direct coculture systems and does not contain residual crosslinkers or photoinitiators that hinder cell growth, so the bioink provides a suitable environment for cell proliferation. It should be noted that CellDrive's bioink is biodegradable and offers the possibility of introducing specific sequences to control different properties depending on the needs of the application.
The financing received will help the business growth of Celldrive 3D over the next two years, which hopes to bring its technology to a market with high growth potential in the short term through a progressive business model.